FR3100449B1 - Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes - Google Patents

Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes Download PDF

Info

Publication number
FR3100449B1
FR3100449B1 FR1909896A FR1909896A FR3100449B1 FR 3100449 B1 FR3100449 B1 FR 3100449B1 FR 1909896 A FR1909896 A FR 1909896A FR 1909896 A FR1909896 A FR 1909896A FR 3100449 B1 FR3100449 B1 FR 3100449B1
Authority
FR
France
Prior art keywords
pain
prevention
treatment
nmn
corresponding compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1909896A
Other languages
English (en)
Other versions
FR3100449A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1909896A priority Critical patent/FR3100449B1/fr
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to PCT/EP2020/075085 priority patent/WO2021048129A1/fr
Priority to CA3153239A priority patent/CA3153239A1/fr
Priority to US17/640,204 priority patent/US20220323477A1/en
Priority to JP2022515517A priority patent/JP2022547937A/ja
Priority to CN202080065872.XA priority patent/CN114423439A/zh
Priority to AU2020344820A priority patent/AU2020344820A1/en
Priority to RS20240277A priority patent/RS65256B1/sr
Priority to ES20765054T priority patent/ES2974641T3/es
Priority to EP20765054.0A priority patent/EP4028021B1/fr
Publication of FR3100449A1 publication Critical patent/FR3100449A1/fr
Application granted granted Critical
Publication of FR3100449B1 publication Critical patent/FR3100449B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention porte sur le nicotinamide mononucléotide, un de ses dérivés pharmaceutiquement acceptables ou un de ses sels pharmaceutiquement acceptables pour son utilisation dans la prévention et/ou le traitement de la douleur ainsi que les compositions le comprenant.
FR1909896A 2019-09-09 2019-09-09 Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes Active FR3100449B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1909896A FR3100449B1 (fr) 2019-09-09 2019-09-09 Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes
ES20765054T ES2974641T3 (es) 2019-09-09 2020-09-08 Uso del NMN para la prevención y/o el tratamiento del dolor y composiciones correspondientes
US17/640,204 US20220323477A1 (en) 2019-09-09 2020-09-08 Use of nmn for the prevention and/or treatment of pain, and corresponding compositions
JP2022515517A JP2022547937A (ja) 2019-09-09 2020-09-08 疼痛の予防および／または処置のためのｎｍｎの使用および対応する組成物
CN202080065872.XA CN114423439A (zh) 2019-09-09 2020-09-08 Nmn用于预防和/或治疗疼痛的用途及相应组合物
AU2020344820A AU2020344820A1 (en) 2019-09-09 2020-09-08 Use of NMN for the prevention and/or treatment of pain, and corresponding compositions
PCT/EP2020/075085 WO2021048129A1 (fr) 2019-09-09 2020-09-08 Utilisation de nmn pour la prévention et/ou le traitement de la douleur et compositions correspondantes
CA3153239A CA3153239A1 (fr) 2019-09-09 2020-09-08 Utilisation de nmn pour la prevention et/ou le traitement de la douleurnet compositions correspondantes
EP20765054.0A EP4028021B1 (fr) 2019-09-09 2020-09-08 Utilisation de nmn pour la prévention et/ou le traitement de la douleur et compositions correspondantes
RS20240277A RS65256B1 (sr) 2019-09-09 2020-09-08 Upotreba nmn za prevenciju i/ili lečenje bola i odgovarajuće kompozicije

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1909896A FR3100449B1 (fr) 2019-09-09 2019-09-09 Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes
FR1909896 2019-09-09

Publications (2)

Publication Number Publication Date
FR3100449A1 FR3100449A1 (fr) 2021-03-12
FR3100449B1 true FR3100449B1 (fr) 2022-08-26

Family

ID=68654773

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1909896A Active FR3100449B1 (fr) 2019-09-09 2019-09-09 Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes

Country Status (1)

Country Link
FR (1) FR3100449B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984379C (fr) * 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Ciblage de nad+ pour traiter la deficience cognitive, les neuropathies et l'inactivite induites par la chimiotherapie et la radiotherapie
CA2994553C (fr) 2015-08-05 2022-08-30 Metro International Biotech, Llc Derives de nicotinamide mononucleotide et leur utilisations
CN109125338A (zh) * 2018-08-30 2019-01-04 泓博元生命科技（深圳）有限公司 一种促进神经系统修复的组合物及其制备方法与应用

Also Published As

Publication number Publication date
FR3100449A1 (fr) 2021-03-12

Similar Documents

Publication Publication Date Title
MX2020007092A (es) Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos.
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
TN2017000158A1 (en) Carbazole derivatives
PH12016502353A1 (en) Pharmaceutical composition
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
PH12019502330A1 (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
TW201613577A (en) Pharmaceutical combinations
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
FR3106056B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes
CR20210460A (es) Compuestos útiles en la terapia del vih
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2021002322A (es) Nuevos metodos.
MX2021001612A (es) Compuestos utiles en terapia del vih.
FR3108032B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
FR3100449B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes
FR3103702B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210312

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5